8C8 Stock Overview
A clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CNBX Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.28 |
| 52 Week High | US$19.68 |
| 52 Week Low | US$7.26 |
| Beta | 1.6 |
| 11 Month Change | 0% |
| 3 Month Change | 0.73% |
| 1 Year Change | -53.38% |
| 33 Year Change | -74.15% |
| 5 Year Change | -91.77% |
| Change since IPO | -70.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8C8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | 1.1% |
| 1Y | -53.4% | -16.7% | 12.5% |
Return vs Industry: 8C8 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 8C8 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 8C8 volatility | |
|---|---|
| 8C8 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8C8's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 8C8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 10 | Eyal Barad | www.cnbxpharma.com |
CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer.
CNBX Pharmaceuticals Inc. Fundamentals Summary
| 8C8 fundamental statistics | |
|---|---|
| Market cap | €4.48m |
| Earnings (TTM) | -€4.34m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs 8C8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8C8 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.57m |
| Earnings | -US$4.57m |
Last Reported Earnings
Feb 28, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -204.5% |
How did 8C8 perform over the long term?
See historical performance and comparison